Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose peginterferon alfa-2a plus ribavirin retreatment in HIV/HCV-coinfected cirrhotic non-responders
2009-009438-34Phase 2Active
- Sponsor
- Luis Fernando López Cortés
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection, human immunodeficiency virus infection (HIV) and Cirrhosis, sponsored by Luis Fernando López Cortés. Primary endpoint: Sustained virologic response. Started Mar 2009; status: active.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)Cirrhosis
Beyond the preview
Go deeper on 2009-009438-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009438-34.